The historical rank and industry rank for Marinomed Biotech AG's Net Margin % or its related term are showing as below:
WBO:MARI'
s Net Margin % Range Over the Past 10 Years
Min: -324.75 Med: -72.13 Max: 234.27
Current: 234.27
WBO:MARI's Net Margin % is ranked better than 98.73% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs WBO:MARI: 234.27
Marinomed Biotech AG (WBO:MARI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Marinomed Biotech AG Net Margin % Related Terms
Marinomed Biotech AG Net Margin % Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (WBO:MARI) has a Net Margin % of -526.71% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #12 out of 946 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Marinomed Biotech AG's Net Margin % too high?
Marinomed Biotech AG's current Net Margin % is -526.71%. Based on the distribution chart, Marinomed Biotech AG ranks #12 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #12 out of 946 companies for Net Margin %. This places Marinomed Biotech AG in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Net Margin % is -526.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.48, compared to a current price of €9.25 — trading 49.9% below its estimated fair value. The current Net Margin % is -526.71%. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Net Margin % is -526.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €9.25 is trading 49.9% below its estimated GF Value™ of €18.48.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
Net Margin %: -526.71%
GF Value™: €18.48 vs. price of €9.25 (49.9% below fair value)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
